<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972061</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13020474</org_study_id>
    <nct_id>NCT01972061</nct_id>
  </id_info>
  <brief_title>Foot/Hand Neuromodulation for Overactive Bladder (OAB)</brief_title>
  <acronym>FootStim</acronym>
  <official_title>Foot/Hand Neuromodulation for Overactive Bladder (OAB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if electrical stimulation of the foot is effective
      in the treatment of overactive bladder conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Foot neuromodulation is designed to treat OAB conditions by electrically stimulating the
      somatic afferent nerves in the foot using skin surface electrodes. The foot stimulation is
      non-invasive, can be performed at home, and has no adverse effects. Foot neuromodulation
      therapy will likely be accepted by more patients and have the potential to make a broader
      impact on the improvement of OAB conditions.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Voiding frequency per day</measure>
    <time_frame>3 weeks</time_frame>
    <description>Voiding diary will be used to record the time of each void during a 24-hour period. A 3-week voiding diary will be collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine volume per void</measure>
    <time_frame>3 weeks</time_frame>
    <description>Voiding diary will be used to record the urine volume per void during a 24-hour period. A 3-week voiding diary will be collected.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of incontinence per day</measure>
    <time_frame>3 weeks</time_frame>
    <description>Voiding diary will be used to record the number of incontinence during a 24-hour period. A 3-week voiding diary will be collected</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>CMG group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Foot stimulation will be applied during a cystometrogram (CMG).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 hours group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Foot stimulation will be applied daily for 3 hours in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1/2 hour group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Foot stimulation will be applied daily for 1/2 hour in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 hour hand group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hand stimulation will be applied daily for 3 hours in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Foot stimulation</intervention_name>
    <description>Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.</description>
    <arm_group_label>CMG group</arm_group_label>
    <arm_group_label>3 hours group</arm_group_label>
    <arm_group_label>1/2 hour group</arm_group_label>
    <arm_group_label>3 hour hand group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 year old men and women and older

          2. Currently having overactive bladder (OAB) symptoms, i.e. urgency, frequency, or
             incontinence

          3. No evidence of neurological disorder or urinary tract infection, i.e. clinically
             diagnosed as idiopathic OAB

        Exclusion Criteria:

          1. Pregnant women in their late pregnancy phase will be excluded because the increasing
             size of the baby/uterus may cause overactive bladder.

          2. Patients with implanted electrical stimulators such as pacemaker will be excluded for
             potential interference with the TENS stimulator.

          3. Patients who are allergic to Cipro or Bactrim will be excluded from the CMG study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Chermansky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dawn McBride, RN</last_name>
    <role>Study Director</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Christopher J Chermansky, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

